Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.

about

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

P2860

Q47221234-46F1B604-E430-47DC-B8AA-92C03B87B311

P2860

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.

Item

http://www.wikidata.org/entity/Q38640435

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Olaratumab: A Novel Platelet-D ...... Advanced Soft Tissue Sarcoma.

@en

type

Item

label

Olaratumab: A Novel Platelet-D ...... Advanced Soft Tissue Sarcoma.

@en

prefLabel

Olaratumab: A Novel Platelet-D ...... Advanced Soft Tissue Sarcoma.

@en

P1476

Olaratumab: A Novel Platelet-D ...... Advanced Soft Tissue Sarcoma.

@en

P2093

Arpita Gandhi

http://www.w3.org/2001/XMLSchema#string

Benjamin J Andrick

http://www.w3.org/2001/XMLSchema#string

P2860

Clinically Relevant Molecular Subtypes in Leiomyosarcoma

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

New members of the platelet-derived growth factor family of mitogens.

Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival.

Biology of platelet-derived growth factor and its involvement in disease.

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

P304

1060028017723935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017723935

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28778132

http://www.w3.org/2001/XMLSchema#string

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.

about

P2860

P2860

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698